215 related articles for article (PubMed ID: 16237810)
21. [Hepatic diseases caused by drugs].
Lammert F; Matern S
Praxis (Bern 1994); 1997 Jul; 86(29-30):1167-71. PubMed ID: 9333916
[TBL] [Abstract][Full Text] [Related]
22. Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis.
Saibara T; Onishi S; Ogawa Y; Yoshida S; Enzan H
Lancet; 1999 May; 353(9166):1802. PubMed ID: 10348023
[No Abstract] [Full Text] [Related]
23. Mitochondria: the gateway for tamoxifen-induced liver injury.
Ribeiro MP; Santos AE; Custódio JB
Toxicology; 2014 Sep; 323():10-8. PubMed ID: 24881593
[TBL] [Abstract][Full Text] [Related]
24. Fatty liver and drugs: the two sides of the same coin.
Miele L; Liguori A; Marrone G; Biolato M; Araneo C; Vaccaro FG; Gasbarrini A; Grieco A
Eur Rev Med Pharmacol Sci; 2017 Mar; 21(1 Suppl):86-94. PubMed ID: 28379591
[TBL] [Abstract][Full Text] [Related]
25. Tamoxifen induced hepatotoxicity in breast cancer patients with pre-existing liver steatosis: the role of glucose intolerance.
Elefsiniotis IS; Pantazis KD; Ilias A; Pallis L; Mariolis A; Glynou I; Kada H; Moulakakis A
Eur J Gastroenterol Hepatol; 2004 Jun; 16(6):593-8. PubMed ID: 15167162
[TBL] [Abstract][Full Text] [Related]
26. Three cases of severe acute hepatitis after parenteral administration of amiodarone: the active ingredient is not the only agent responsible for hepatotoxicity.
Giannattasio F; Salvio A; Varriale M; Picciotto FP; Di Costanzo GG; Visconti M
Ann Ital Med Int; 2002; 17(3):180-4. PubMed ID: 12402666
[TBL] [Abstract][Full Text] [Related]
27. [A case of steatohepatitis associated with tamoxifen].
Kanda T; Yokosuka O; Chiba T; Kojima H; Fukai K; Imazeki F; Saisho H
Nihon Shokakibyo Gakkai Zasshi; 2002 Sep; 99(9):1119-21. PubMed ID: 12355903
[No Abstract] [Full Text] [Related]
28. Chemotherapy-associated steatohepatitis.
Meunier L; Larrey D
Ann Hepatol; 2020; 19(6):597-601. PubMed ID: 32061473
[TBL] [Abstract][Full Text] [Related]
29. Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease.
Liew PL; Lee WJ; Lee YC; Wang HH; Wang W; Lin YC
Obes Surg; 2006 Dec; 16(12):1584-93. PubMed ID: 17217634
[TBL] [Abstract][Full Text] [Related]
30. Effects of tamoxifen on hepatic fat content and the development of hepatic steatosis in patients with breast cancer: high frequency of involvement and rapid reversal after completion of tamoxifen therapy.
Nishino M; Hayakawa K; Nakamura Y; Morimoto T; Mukaihara S
AJR Am J Roentgenol; 2003 Jan; 180(1):129-34. PubMed ID: 12490491
[TBL] [Abstract][Full Text] [Related]
31. Granular cells as a marker of early amiodarone hepatotoxicity.
Jain D; Bowlus CL; Anderson JM; Robert ME
J Clin Gastroenterol; 2000 Oct; 31(3):241-3. PubMed ID: 11034006
[TBL] [Abstract][Full Text] [Related]
32. [Pseudo-alcoholic hepatitis and cirrhosis caused by amiodarone (Cordarone)].
Lamproye A; Ramos J; Larrey D; Belaiche J
Rev Med Liege; 1998 Mar; 53(3):121-4. PubMed ID: 9594610
[TBL] [Abstract][Full Text] [Related]
33. Non-alcoholic steatohepatitis in children.
Nanda K
Pediatr Transplant; 2004 Dec; 8(6):613-8. PubMed ID: 15598336
[TBL] [Abstract][Full Text] [Related]
34. Diagnosis and interpretation of steatosis and steatohepatitis.
Burt AD; Mutton A; Day CP
Semin Diagn Pathol; 1998 Nov; 15(4):246-58. PubMed ID: 9845426
[TBL] [Abstract][Full Text] [Related]
35. Cirrhosis with steatohepatitis after adjuvant tamoxifen.
Oien KA; Moffat D; Curry GW; Dickson J; Habeshaw T; Mills PR; MacSween RN
Lancet; 1999 Jan; 353(9146):36-7. PubMed ID: 10023952
[No Abstract] [Full Text] [Related]
36. Drug-induced fatty liver disease: An overview of pathogenesis and management.
Satapathy SK; Kuwajima V; Nadelson J; Atiq O; Sanyal AJ
Ann Hepatol; 2015; 14(6):789-806. PubMed ID: 26436351
[TBL] [Abstract][Full Text] [Related]
37. [Clinic-epidemiological significance of drug hepatotoxicity in liver disease consultation].
Jmelnitzky AC; Guidi M; Bologna A; Viola M; Soccini C; Barbero R; Belloni P; Apraiz M
Acta Gastroenterol Latinoam; 2000; 30(2):77-84. PubMed ID: 10925723
[TBL] [Abstract][Full Text] [Related]
38. CYP17 polymorphism as a risk factor of tamoxifen-induced hepatic steatosis in breast cancer patients.
Ohnishi T; Ogawa Y; Saibara T; Nishioka A; Kariya S; Fukumoto M; Onishi S; Yoshida S
Oncol Rep; 2005 Mar; 13(3):485-9. PubMed ID: 15706422
[TBL] [Abstract][Full Text] [Related]
39. Invasive and non-invasive investigations for tamoxifen-induced non-alcoholic steatohepatitis (NASH): the benefit of computed tomography scan guided liver biopsy.
Ahmed MH; Osman KA; Osman MM
Pathology; 2006 Jun; 38(3):270-1. PubMed ID: 16753757
[No Abstract] [Full Text] [Related]
40. A myriad of pathways to NASH.
Larrain S; Rinella ME
Clin Liver Dis; 2012 Aug; 16(3):525-48. PubMed ID: 22824479
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
